Jiangsu Hengrui Pharmaceuticals (600276.SH): Application for market approval of Imatinib Sulfate tablets accepted.

Jiangsu Hengrui Pharmaceuticals (600276.SH) announced that the company has recently received a "Acceptance Notice" issued by the National Medical Products Administration (referred to as the "NMPA"). The company's application for the marketing authorization of the drug Imatinib Sulfate Tablets has been accepted by the NMPA. Imatinib Sulfate Tablets have been approved for marketing in China for four indications, including: for adult patients with active ankylosing spondylitis who have inadequate response to or intolerance to one or more TNF inhibitors; for adult patients with moderate to severe active rheumatoid arthritis who have inadequate response to or intolerance to one or more TNF inhibitors; for adult patients with moderate to severe atopic dermatitis who have inadequate response to or intolerance to topical or other systemic treatments; and for adult patients with severe alopecia areata.